Non Small Cell Lung Cancer Clinical Trials in Saint Paul, Minnesota

7 studies are recruiting for non small cell lung cancer in Saint Paul, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Saint Paul, Minnesota

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

   The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Saint Paul, Minnesota

   Locations

   167 in total

   Run by

   AstraZeneca

   See if you can join NCT06350097 on ClinicalTrials.gov

3. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

   This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Park Nicollet Institute, Saint Paul, Minnesota

   Locations

   260 in total

   Run by

   Summit Therapeutics

   See if you can join NCT05899608 on ClinicalTrials.gov

4. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Allina Health Cancer Institute - United Hospital, Saint Paul, Minnesota

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

5. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HealthPartners Cancer Research Center (Regions Hospital), Saint Paul, Minnesota

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

6. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

   The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Regions Hospital, Saint Paul, Minnesota

   Locations

   372 in total

   Run by

   Pfizer

   See if you can join NCT06758401 on ClinicalTrials.gov

7. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HealthPartners Cancer Center at Regions Hospital, Saint Paul, Minnesota

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov